Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for Moderate to Severe Forehead Lines in Chinese Adults
CTR20233507Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of botulinum toxin type A in Forehead lines, glabellar furrowing, sponsored by AbbVie Inc.. Started Nov 2023; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Forehead linesglabellar furrowing
Beyond the preview
Go deeper on CTR20233507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233507.